K. Grosios

发表

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®)

H. Petry, F. Salmon, K. Grosios, 2014, Expert review of clinical pharmacology.

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

M. Bibby, G. Pettit, K. Grosios, 1999, British Journal of Cancer.

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.

M. Bibby, P. Loadman, D. Swaine, 2000, Anticancer research.

Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.

P. Cooper, M. Bibby, S. Shnyder, 2002, Anticancer research.

Medullary Thyroid Cancer Cells inCalcitonin Gene Expression through Distinct Mechanisms The RET Kinase Inhibitor NVP-AST 487 Blocks Growth and Updated

D. Fabbro, H. Lane, M. Santoro, 2007 .

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

Paul D. Smith, R. Wilkinson, B. Barlaam, 2010, Clinical Cancer Research.

Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis

K. Grosios, J. Dawson, J. Wood, 2004, Inflammation Research.

Healthcare in the UK – Predictive, Preventive and Personalised Medicine Perspective at the Beginning of the Twenty-First Century

P. Gahan, K. Grosios, Jane Burbidge, 2012 .

Original Research Papers Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis

K. Grosios, J. Dawson, A. Platform, 2004 .

Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2

A. Markham, K. Grosios, A. Markham, 2002, Cytogenetic and Genome Research.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer research.

Adeno-Associated Virus Gene Therapy and Its Application to the Prevention and Personalised Treatment of Rare Diseases

H. Petry, J. Lubelski, K. Grosios, 2015 .

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Christine Stephan, Doriano Fabbro, Giorgio Caravatti, 2007, Cancer research.

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

C. Figdor, M. Middleton, P. Ottevanger, 2021, BMJ Open.

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer Research.

UCN-01 Kyowa Hakko Kogyo Co.

K. Grosios, 2001, Current opinion in investigational drugs.

Noninvasive monitoring of changes in structural cancellous bone parameters with a novel prototype micro-CT

Andres Laib, Jürg A. Gasser, Bruno Koller, 2009, Journal of Bone and Mineral Metabolism.

Tyrosine kinase targets in drug discovery

P. Traxler, Peter Traxler, Konstantina Grosios, 2003 .

Overview of healthcare in the UK

Peter B. Gahan, P. Gahan, Konstantina Grosios, 2010, EPMA Journal.